Jul 9, 2026 · 7 min
Deutz bets on defense as AstraZeneca trial disappoints
Deutz Buy, Astrazeneca's Trial, Computacenter Up
The episode shows how European defense spending, biotech setbacks, and corporate earnings are pulling markets in sharply different directions.
- 1Deutz is buying FFG for €1.6 billion to expand into Europe’s growing defense market.
- 2AstraZeneca shares fell after disappointing clinical results for its gene-silencing drug Wainua.
- 3Computacenter delivered strong performance and doubled its first-half profit expectations.
Don't miss
Deutz’s €1.6 billion purchase of FFG links a traditional German engine maker directly to Europe’s rising defense spending.
The brief
Hosts Caroline Hepker and Lizzie Burden introduce a European market report with Bloomberg reporter Chloe Melley, whose focus is three sharply contrasting stock movers.
Deutz is paying €1.6 billion for defense firm FFG, positioning the German engine maker to benefit from Europe’s rising military spending.
AstraZeneca’s stock moved lower after disappointing clinical trial results for Wainua, its gene-silencing drug, underscoring the market risk around biotech development.
Computacenter provides the counterpoint: strong performance led the IT services company to double its first-half profit expectations and offer a more positive outlook.
Together, the three cases show how defense demand, clinical evidence, and earnings momentum are reshaping the European stock landscape in different ways.
What was said on this episode
5 statements · 3 positive · 2 negative
Defense-sector dealmaking activity is picking up.
“there's a bit of a pickup there in terms of deal making activity with the Deutsche Steel”
Listen at 2:07
Wainua failed to reduce cardiovascular events or related deaths.
“Wainua did not manage to do that and to reduce cardiovascular events or death related to heart problems”
Listen at 3:03
A successful Wainua trial could have generated billions in additional sales.
“a successful trial could have led to billions of dollars more in sales”
Listen at 3:15
Wainua’s trial is a strategic setback for AstraZeneca’s disease-area ambitions.
“it's also a strategic setback because AstraZeneca has been really looking to establish itself in that disease area”
Listen at 3:20
Computacenter shares have gained 56% year to date.
“brings year to date gains at 56%”
Listen at 4:28
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
Mentioned
Deutz AG
FFG Flensburger Fahrzeugbau Gesellschaft mbH
Wainua (Eplontersen)
ComputacenterListen to the full episode and explore every guest, topic, and moment on PodLume.